Clinical Implication of Cyclophosphamide in Oncology, Hematology and Bone Marrow Transplantation (BMT)


Authors : Dastan Salim Hassan; Hemin Jumaa Majeed Hasary

Volume/Issue : Volume 7 - 2022, Issue 5 - May

Google Scholar : https://bit.ly/3IIfn9N

Scribd : https://bit.ly/3xYxWo1

DOI : https://doi.org/10.5281/zenodo.6655187

Cyclophosphamide (Cytoxan; Cy) is an alkylating agent with immunosuppressive and cytotoxic action. The origin compound is out of action in vitro and utilizesits biologic activity over metabolites, principally phosphoramide mustard stemming from hepatic microsomal enzymes. The accurate process of cytotoxic and immunosuppressive activity of Cy at the cellular level is not ultimately presumed. Myelosuppression, alopecia, hemorrhagic cystitis, and gonadal disturbance are the main harmful consequence. Applicable information proposesthat Cy has carcinogenic probable in humans. Cy is greatly utilized as chemotherapy for cancer treatment, also as an immunosuppressive chemical, it is profitably used in specific nonmalignant diseases whether autoimmune phenomena are entrenched or suspicious in the pathogenesis of the disease. It is the preferred drug in Wegener's granulomatosis. Broad efforts are being made to generate Cy analogues with higher selective cytotoxic and immunosuppressive activity.

Keywords : Cyclophosphamide, cyclophosphamide and cancer, chemotherapy, toxic effect.

CALL FOR PAPERS


Paper Submission Last Date
29 - February - 2024

Paper Review Notification
In 1-2 Days

Paper Publishing
In 2-3 Days

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe